Emerging Issue of Inflammatory Bowel Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 December 2024 | Viewed by 394

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gastroenterology with Endoscopy Unit, Medical University of Lublin, 20-954 Lublin, Poland
Interests: liver; alcohol-related liver disease; liver steatosis; liver fibrosis; autoimmune liver diseases; inflammatory bowel disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammatory bowel diseases (IBDs) are currently crucial pathologies. We still do not know their exact origin, and despite the ongoing era of biologics in their treatment, Crohn’s disease and ulcerative colitis tend to be somehow unpredictable in their course. Furthermore, they concern mostly young people, significantly affecting the quality of everyday life. We gather continuously more information related to IBDs; nevertheless, some essential issues are still to be resolved. To emphasize the current role of IBDs and to explore molecular pathways involved in their development, we highly encourage you to publish in the Special Issue of Biomedicines titled Emerging Issue of Inflammatory Bowel Diseases.

The scope of the manuscripts should be related to the following topics:

  • Original data on novel markers in the diagnosis IBDs and in the prediction of their flare up;
  • Possible new indicators of the positive treatment response;
  • New approaches in the management of IBDs, including combinations of biologics;
  • Markers predicting the natural history of IBDs;
  • Comorbidities observed in patients with IBDs and the general outcome in this population;
  • The context of colorectal cancer in patients with IBDs;
  • Future perspectives for IBDs, including medical and social aspects.

Dr. Agata Michalak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel diseases
  • strategies
  • biologics
  • perspectives
  • markers
  • complications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1923 KiB  
Article
Evaluation of Selenium Concentrations in Patients with Crohn’s Disease and Ulcerative Colitis
by Michał Chalcarz, Beniamin Oskar Grabarek, Tomasz Sirek, Agata Sirek, Piotr Ossowski, Mateusz Wilk, Katarzyna Król-Jatręga, Konrad Dziobek, Julia Gajdeczka, Jarosław Madowicz, Damian Strojny, Kacper Boroń and Jakub Żurawski
Biomedicines 2024, 12(10), 2167; https://doi.org/10.3390/biomedicines12102167 - 24 Sep 2024
Viewed by 297
Abstract
Background/Objectives: In this study, serum selenium levels in patients with Crohn’s disease (CD) and ulcerative colitis (UC) were evaluated to identify potential predictive markers of disease activity. Conducted in 100 inflammatory bowel disease (IBD) patients (54 CD, 46 UC) and 100 healthy controls, [...] Read more.
Background/Objectives: In this study, serum selenium levels in patients with Crohn’s disease (CD) and ulcerative colitis (UC) were evaluated to identify potential predictive markers of disease activity. Conducted in 100 inflammatory bowel disease (IBD) patients (54 CD, 46 UC) and 100 healthy controls, this research provides novel insights through focusing on the regional selenium status of people with IBD in the Polish population, a demographic with limited existing data. Methods: Selenium concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS). Results: Significantly lower levels of selenium were observed in CD (64.79 µg/L ± 12.15 µg/L) and UC (68.61 µg/L ± 11.43 µg/L) patients when compared with the controls (90.52 ± 12.00 µg/L, p < 0.0001). Regression analysis identified leukocyte and erythrocyte counts and bilirubin as significant predictors of selenium levels in UC patients, while no significant predictors were found for CD. Conclusions: The findings suggest that selenium deficiency is linked to IBD and may serve as a non-invasive biomarker for disease severity, particularly in UC. This practical approach offers a potential alternative to invasive procedures such as endoscopy for monitoring disease progression. However, further research is needed to confirm these findings in larger populations and explore the therapeutic role of selenium supplementation in IBD management. Full article
(This article belongs to the Special Issue Emerging Issue of Inflammatory Bowel Diseases)
Show Figures

Figure 1

Back to TopTop